Substantiated value rose 0.8% to 275.9 MSEK, driven by Olik's strong growth and stable Lara valuation. Lara's clinics and lending surged year-over-year, while Olik's revenue and EBITDA grew sharply. Portfolio valuations remain sensitive to discount rates and currency.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.